C000218947 Performance — AVIP Constellation Managed Risk Balanced Portfolio, Class I
Data updated: 2026-08-26
C000218947 returned +6.88% year to date and +14.37% over one year to Jun 2026. Annualised returns are +11.63% over 3 years and +5.34% over 5 years. The fund trailed its US Multi-Cap Blend category average: $100 invested three years ago grew to $139, against $143 for the category, and to $114 over one year, against $116. Volatility over the past three years was 8.60% a year. In the 12 months to Jun 2026 the fund lost a net $39.9M, and assets reached $487.65M.
C000218947 Growth of $100
What $100 invested in AVIP Constellation Managed Risk Balanced Portfolio grew to, compounded from monthly returns reported on SEC Form N-PORT, against the US Multi-Cap Blend category average over the same months.
| Period | C000218947 | Category average |
|---|---|---|
| 1 year (Jul 2025 – Jun 2026) | $114 | $116 |
| 3 years (Jul 2023 – Jun 2026) | $139 | $143 |
| 5 years (Jul 2021 – Jun 2026) | $130 | $136 |
| Since data start (Apr 2021 – Jun 2026) | $130 | $142 |
C000218947 Trailing Returns
Total returns to Jun 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +6.88% |
| 1 year | +14.37% |
| 3 years (annualised) | +11.63% |
| 5 years (annualised) | +5.34% |
C000218947 Annual Returns
Calendar-year total returns of AVIP Constellation Managed Risk Balanced Portfolio, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jun) | +6.88% |
| 2025 | +13.30% |
| 2024 | +9.16% |
| 2023 | +13.86% |
| 2022 | −15.83% |
| 2021 (Apr–Dec) | +2.29% |
C000218947 Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.3% | +1.1% | −4.2% | +5.8% | +3.2% | −0.2% | — | — | — | — | — | — |
| 2025 | +1.7% | +0.3% | −2.5% | 0.0% | +3.2% | +3.1% | +0.7% | +1.8% | +2.4% | +1.5% | +0.4% | +0.1% |
| 2024 | 0.0% | +1.7% | +2.1% | −2.8% | +3.2% | +1.2% | +1.9% | +2.2% | +1.9% | −2.4% | +2.4% | −2.3% |
| 2023 | +5.4% | −3.0% | +3.1% | +1.1% | −1.3% | +2.9% | +1.8% | −1.8% | −3.4% | −2.2% | +6.8% | +4.2% |
| 2022 | −3.2% | −2.1% | −0.1% | −5.8% | +0.8% | −5.1% | +4.8% | −3.5% | −6.2% | +1.7% | +5.0% | −2.6% |
| 2021 | — | — | — | 0.0% | 0.0% | −0.1% | +0.8% | +1.1% | −2.5% | +2.5% | −1.4% | +1.9% |
C000218947 Risk
Risk measures from monthly returns over Jul 2023 – Jun 2026.
- 3-year volatility (annualised): 8.60%
- 3-year Sharpe ratio: 0.83 (vs 4.5% risk-free rate)
- Best month: +6.84% (Nov 2023)
- Worst month: −4.16% (Mar 2026)
C000218947 Fund Flows
Monthly money in and out of AVIP Constellation Managed Risk Balanced Portfolio, from SEC Form N-PORT.
- 12-month net flow: −$39.9M
- 12-month gross sales (incl. reinvestments): $75.6M
- Sales ÷ redemptions: 0.65×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jun 2026 | $43.9M | $9.0M | $34.9M |
| May 2026 | $1.2M | $8.4M | −$7.3M |
| Apr 2026 | $783K | $10.0M | −$9.2M |
| Mar 2026 | $1.1M | $9.5M | −$8.4M |
| Feb 2026 | $1.7M | $8.7M | −$7.0M |
| Jan 2026 | $512K | $7.5M | −$7.0M |
| Dec 2025 | $455K | $9.4M | −$9.0M |
| Nov 2025 | $1.5M | $8.7M | −$7.3M |
| Oct 2025 | $1.4M | $9.6M | −$8.2M |
| Sep 2025 | $15.8M | $14.2M | $1.6M |
| Aug 2025 | $6.5M | $11.1M | −$4.7M |
| Jul 2025 | $830K | $9.4M | −$8.6M |
C000218947 Assets Under Management
Net assets of AVIP Constellation Managed Risk Balanced Portfolio by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-06-30 | $487.65M |
| 2026-03-31 | $470.76M |
| 2025-12-31 | $501.73M |
| 2025-09-30 | $516.89M |
| 2025-06-30 | $517.07M |
| 2025-03-31 | $513.03M |
| 2024-12-31 | $538.21M |
| 2024-09-30 | $578.89M |
| 2024-06-30 | $568.83M |
| 2024-03-31 | $587.92M |
| 2023-12-31 | $587.31M |
| 2023-09-30 | $565.45M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.